TIMP-1 Alters Susceptibility to Carcinogenesis

Jin-Sae Rhee,1,2 Robert Diaz,2 Lidiya Korets,2 J. Graeme Hodgson,3 and Lisa M. Coussens2,4,5

1Medical Scientist Training Program, 2Cancer Research Institute, Departments of 3Laboratory Medicine, 4Pathology, and 5Comprehensive Cancer Center, University of California, San Francisco, California

ABSTRACT

Tissue inhibitors of metalloproteinases (TIMPs) are a family of multifunctional proteins known to possess a broad range of biological activities, including inhibition of metalloproteinase activity, regulation of proliferation and apoptosis of a variety of cell types, and, depending on the context, differential regulation of angiogenic and inflammatory responses. Elevated mRNA expression of TIMP family members correlates with malignancy and clinical outcome in many human cancer types; however, a protective role for TIMPs also has been observed in various mouse models of human cancer. In the current study, we found distinct spatial-temporal expression patterns for the mRNA of TIMP family members in a mouse model of epithelial carcinogenesis [i.e., keratin 14-human papillomavirus 16 (K14-HPV16) transgenic mice]. To test the hypothesis that elevated expression of TIMP-1 functionally regulates epithelial carcinogenesis, we introduced a human TIMP-1 transgene into K14-HPV16 transgenic mice and assessed neoplastic progression. Results from these studies suggest that TIMP-1 enhances tumorigenecity by potentiating keratinocyte hyperproliferation and appearance of chromosomal aberrations in premalignant cells, thereby increasing their risk to undergo malignant conversion. In addition, TIMP-1 inhibits tissue gelatinolytic activity in tumor stroma, affects stabilization of collagen fibrils, but does not inhibit malignant conversion of dysplasias into carcinomas or development of metastases. The combined implications of these studies suggest that TIMP-1 is an important contributor to epithelial neoplastic progression and supports the concept that TIMP-1 exerts differential regulation on tissues in a stage-dependent manner.

INTRODUCTION

Tissue inhibitors of metalloproteinases (TIMPs) are a family of four multifunctional proteins numbered in order of their discovery and characterized by a conserved structure ranging from Mr 20,000 to 30,000 that inhibits metalloproteinase (MP) activity, specifically matrix metalloproteinase (MMP) activities in a one-to-one stoichiometry (1). Although named for their ability to inhibit MP activity, TIMPs also possess other important bioactivities (2–4). TIMP-1, identified originally for its erythroid-potentiating activity (5), induces proliferation in a wide range of cell types (6–8) by mechanisms that are apparently independent of MMPs (9). In addition, TIMP-1 is known to promote activation of angiogenesis (4, 10, 11), regulate apoptosis (12), amplify inflammation (13), and regulate metastasis formation (14). Similar pleiotropic activities have also been demonstrated for TIMP-2 (15), TIMP-3 (16), and TIMP-4 (17).

TIMP-1 mRNA expression is up-regulated in many human cancer types and in some cases correlates with more severe clinical outcome (e.g., colorectal carcinoma, non-small cell lung carcinoma and breast carcinoma; Ref. 18). Studies in experimental mouse models have revealed paradoxically that TIMP-1 can exhibit proneoplastic and antineoplastic effects during primary and metastatic tumor development (14, 19–24).

In the current study, we have sought to critically examine the spatial-temporal expression patterns of TIMP mRNA and to evaluate the functional significance of TIMP-1 expression during de novo epithelial carcinogenesis using a transgenic mouse model of skin carcinoma development [e.g., keratin 14-human papillomavirus 16 (K14-HPV16) transgenic mice; Refs. 25–27]. In K14-HPV16 transgenic mice, the expression of HPV16 early region genes has been targeted to basal keratinocytes (28); animals are born phenotypically normal, and by age 1 month with 100% penetrance, transgenic skin becomes uniformly hyperplastic. These benign lesions advance focally into broad hyperproliferative dysplastic lesions present in 100% of mice age 4–6 months. By age 1 year, ~60% of mice develop tumors, 50% of which are squamous cell carcinomas (SCCs) that metastasize to regional lymph nodes with an ~30% frequency and 10% of which are locally invasive nonmetastatic microcystic adnexal carcinomas (MACs). Results from the current study suggest that TIMP mRNA are not regulated coordinately during the development and progression of skin carcinogenesis in HPV16 mice and that sustained TIMP-1 expression functionally promotes epithelial carcinogenesis during the early stages of neoplastic progression, whereas in later stages, it inhibits tissue gelatinolytic activity and stabilizes extracellular matrices (ECMs) without affecting metastatic spread.

MATERIALS AND METHODS

Animal Husbandry, Genotype, and Histopathologic Analyses. K14-HPV16 transgenic mice (28), the preparation of tissue sections for histologic examination, and the characterization of neoplastic stages based on H&E histopathology and keratin intermediate filament expression have been described previously (25–27, 29). Tissue samples were fixed by immersion in 10% neutral buffered formalin, dehydrated through graded ethanol and xylene, embedded in paraffin, cut by a Leica 2135 microtome (Wetzlar, Germany) into 5-μm-thick sections, and histopathologically examined after H&E staining and immunoreactivity of keratin intermediate filaments. Hyperplastic lesions were identified by a twofold increase in epidermal thickness and an intact granular cell layer with keratohyalin granules; dysplastic lesions were characterized based on basal and spinous cell layers with hyperchromatic nuclei representing more than half of the total epidermal thickness and incomplete terminal differentiation of keratinocytes; and SCC lesions were noted by an abundance of abnormal mitotic figures and an invasive loss of integrity in the basement membrane with clear development of malignant cell clusters proliferating in the dermal stroma. Characterization of infundibular (MACs) and sebaceous lesions (sebaceous adenomas) was as described previously (27).

The βA-hT1 transgenic mice have been described previously (30). Briefly, these mice contain a transgene in which the human β-actin promoter directs expression of a human TIMP (hTIMP)-1 cDNA, generated initially in the CD1 mouse strain. To minimize the effect of background strain differences in susceptibility to carcinogenesis, βA-hT1 mice were backcrossed a minimum of six generations into the FVB/n strain before intercrossing with K14-HPV16 mice (FVB/n, N15). The βA-hT1 transgenic was followed by PCR genotyping of tail DNA using oligonucleotide primers (5’-GTGGGACACCAGAAGTCATGATGCAAC-3’ and 5’-CTATCTGGACGGACGGACT-3’). DNA was amplified for 30 cycles at 95°C for 60 s, 59°C for 30 s, and 72°C for 120 s to generate a 480-bp product corresponding to a region within the hTIMP-1 cDNA. In all of the analyses, HPV16/βA-hT1+ double transgenic mice were compared with littermate control mice lacking the βA-hT1 transgene (HPV16/βA-hT1−). P values ≤ 0.05 were considered to be statistically significant.
RNA Analysis. Real-time PCR analysis was performed as described previously (27). Total RNA was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommendations and the method of Chomczynski (31) by powdering fresh-frozen tissue samples in liquid nitrogen, homogenizing with a microtubete pestle (USA Scientific, Ocala, FL), and shearing by multiple passages through a syringe and 21-gauge needle (Becton Dickinson, Franklin Lakes, NJ), followed by phenol-chloroform extraction and isopropanol precipitation. Quantification of TIMP-1 mRNA levels was performed on three mice per category as described previously (27).

In situ hybridization was performed as described previously (25) using 35S-labeled riboprobes generated from CDNA containing plasmid templates for mouse TIMP-1 (32), mouse TIMP-2 (33), mouse TIMP-3 (34), mouse TIMP-4 (35), and hTIMP-1 (30). As negative controls, hybridization using sense probes was performed and showed no signal (data not shown).

Protein Analysis. Protein lysates were prepared by grinding fresh-frozen tissue samples from ear, tumor, or lymph nodes in liquid nitrogen and homogenizing in Tris buffer (25 mM Tris (pH 7.6), 5 mM CaCl2, and 0.25% Triton X-100) in a 2-ml tissue grinder (Fisher Scientific, Hampton, NH). After centrifugation at 13,000 × g at 4°C for 30 min, supernatants were measured for protein concentration by the detergent-compatible protein assay (Bio-Rad, Hercules, CA). Serum samples were prepared by extraction of whole blood, coagulated overnight at 4°C, followed by centrifugation at 700 × g at 4°C for 30 min to remove cells. ELISA was performed in 96-well Costar plates (Corning, Corning, NY) prepared by precoating with a mouse monoclonal antibody (Oncogene Research Products, Boston, MA) diluted 1:250 in 50 mM carbonate buffer (pH 9.6) at 4°C overnight, followed by blocking in 1% BSA in PBS at room temperature for 1 h. Plates were washed with buffer (0.1% BSA, 0.05% Tween-20, in PBS) and incubated with either 10 µl serum or 25 µg protein lysate diluted in wash buffer for 3 h. Plates were washed and then processed by incubation with a rabbit polyclonal anti-hTIMP-1 antibody (Oncogene Research Products, Boston, MA) diluted 1:1000 in wash buffer, goat antirabbit biotinylated secondary antibody (Pierce Biotechnology, Rockford, IL) diluted 1:10,000 in wash buffer, and ExtrAvidin peroxidase conjugate (Sigma Chemical Co., St. Louis, MO) diluted 1:1,000 in blocking buffer. Assays were performed with the Quantikine detection system (R&D Systems, Minneapolis, MN) by the manufacturer’s recommendations and quantified at 650 nm on a SpectraMax 340 spectrophotometer (Molecular Devices Corp., Sunnyvale, CA). Samples were assayed from three mice per category, and all of the experiments were repeated three times.

Gelatinase Assay. Protein lysates were generated from fresh-frozen tissue samples as described previously for the ELISA assay. Three µg of protein lysate were incubated at 37°C in reaction buffer [50 mM Tris (pH 7.6), 150 mM NaCl, 5 mM CaCl2, 0.2 mM NaN3, and 0.05% Brij-35] with 400 ng DQ-gelatin (Molecular Probes, Eugene, OR) in a total volume of 200 µl. Samples were analyzed by SDS-PAGE (4%-12% gradient) on a Bio-Rad Mini-PROTEAN III system. After electrophoresis, gels were washed three times for 30 min in 2.5% Triton X-100 and three times for 15 min in ddH2O, incubated overnight at 37°C in 50 mM Tris-HCl and 10 mM CaCl2 (pH 8.2), and then stained in 0.5% Coomassie Blue and destained in 20% methanol and 10% acetic acid. Negative staining indicates the location of active protease bands. Exposure of proenzymes within tissue extracts to SDS during the gel separation procedure leads to activation without proteolytic cleavage (37).

Picrosirius Red Staining. Staining of collagen in tissues by picrosirius red was performed as described previously (38, 39). Five-µm-thick paraffin sections were deparaffinized in xylene, rehydrated in graded ethanol, and stained for 1 h with 0.1% (w/v) solution of sirius red F3B dissolved in saturated aqueous picric acid. Sections were rinsed in 0.5% glacial acetic acid, dehydrated in graded ethanol and xylene, and mounted in Cytoseal 60 (Fisher Scientific). Images were captured at high magnification under normal illumination and polarized light on a Leica DM-RXA microscope attached to a Leica digital camera operated by OpenLab software (Improvision). Presence of mature fibrillar type I collagen was assessed from captured images (40, 41) using the morphometric quantification technique described previously (42). For each field, an image taken under polarized light was quantified for pixel density using a set threshold for detection of the strongly birefringent signal indicative of fibrillar collagen. For the same field, an image under brightfield was quantified for exclusion of regions not to be evaluated (i.e., vessel lumen, ear cartilage, and epithelial compartments). Calculated values represent the percentage of fibrillar collagen, normalized for stromal area, and averaged from four fields per mouse with six mice per category.

Immunohistochemistry. Immunohistochemical detection of antigens was performed as described previously (25). To simultaneously detect keratin 5 and bromodeoxyuridine (BrDU)-positive cells in tissues, animals received i.p. injections of BrdU (Roche, Basel, Switzerland) dissolved in PBS at 50 µg/g total body weight 90 min before animals were killed and tissue samples were prepared. Five-µm-thick paraffin sections were deparaffinized in xylene, rehydrated in graded ethanol, boiled in Citra antigen-retrieval solution (BioGenex, San Ramon, CA), washed in PBS, blocked in 1× blocking buffer (5% normal goat serum/2.5% BSA and PBS), and incubated in a 1:10,000 dilution of a rabbit polyclonal antibody against mouse keratin 5 (Babco, Richmond, CA) in 0.5× blocking buffer overnight at 4°C, followed by a series of PBS washes, incubation of slides with biotinylated donkey secondary antibody against rabbit (Pierce), blocking in 0.6% hydrogen peroxide in methanol, conjugation by ABC-Elite (Vector, Burlingame, CA), and development in Fast-DAβ (Sigma Chemical Co.). BrDU-positive cells were detected essentially as described by the manufacturers’ recommendations using the BrDU Labeling Kit II (Roche), developed by Vector Red Alkaline Phosphatase Kit (Vector), counterstained by H&E, dehydrated by graded ethanol and xylene, and mounted in Cytoseal 60 (Richard-Allan Scientific, Kalamazoo, MI). Five fields per mouse were captured at high magnification (40×) on a Leica DM-RXA microscope attached to a Leica digital camera operated by OpenLab software (Improvision, Lexington, MA). Proliferative index was quantified from five high-power (40×) images per tissue and included five mice per category as the percentage of the BrDU-positive nuclei in keratin 5-positive keratinocytes over the total number of keratin 5-positive keratinocytes.

Apoptotic frequency was assayed on 5-µm-thick paraffin sections, deparaffinized as described previously, and processed for the terminal deoxynucleotidyl transferase-mediated nick end labeling reaction using the fluorescein-FragEL DNA fragmentation detection kit (Oncogene Research Products) by the manufacturer’s recommendations. Apoptotic index was quantified from five high-power (40×) images per tissue and included five mice per category as the percentage of the terminal deoxynucleotidyl transferase-mediated nick end labeling-positive keratinocytes over the total number of 4,6-diamidino-2-phenylindole-stained keratinocytes.

Dual-Color Fluorescent in Situ Hybridization (FISH) on Paraffin Sections

Preparation of Paraffin Sections. Neoplastically staged tissue sections were deparaffinized by incubation at 65°C for 30 min in a heating block, followed by three incubations in xylene for 15 min at 50°C. Xylene was removed by three washes in 100% ethanol for 5 min at room temperature. After rehydration (2-min washes in 85%, 70%, and 50% ethanol), slides were rinsed in 1× PBS at room temperature, incubated in 1× NaScN for 8 min at 80°C, and washed two times in 1× PBS for 5 min at room temperature. The sections were digested with 0.1 mg/ml pepsin (Worthington Biochemicals, Lakewood, NJ) for 4 min at 37°C, rinsed with 1× PBS at 4°C, washed in 1× PBS/0.1% Tween-20 for 5 min at room temperature, and rinsed in ice cold 1× PBS. The sections then were dehydrated (2 min each in 70%, 85%, and 100% ethanol), air dried for 15 min at 37°C, fixed in Carnoy’s solution (3:1 ratio of methanol and acetic acid), and air dried for 30 min at 37°C. In preparation for hybrid-
ization, sections were rehydrated, incubated in 2× SSC for 30 min at 37°C, denatured in 50% formamide/2× SSC for 5 min at 37°C, dehydrated, and then placed on a 37°C slide warmer until the hybridization mixture was added. Once fluorescent in situ hybridization (FISH) probes were placed on sections, the sections were covered with plastic cover strips and placed in plastic slide holders (American Scientific, Columbus, OH) containing a strip of Whatman paper (3 mm) soaked in 750 μl of 50% formamide/2× SSC (pH 7.0). After hybridizing for 48–72 h at 37°C, the slides were washed in three 10-min washes consisting of 50% formamide/2× SSC at 45°C, one 10-min wash in 2× SSC at 45°C, one 10-min wash in 2× SSC at room temperature, one 10-min wash in 4× SSC/0.1% Triton X-100 at room temperature, and two 5-min washes in ddH2O at room temperature. The sections then were counterstained with 1.0 μm 4',6-diamidino-2-phenylindole (Sigma Chemical Co.) in 90% glycerol/1% PBS mounting solution.

Preparation of Hybridization Probes. Probes mapping to consistently amplified regions of chromosome 5 (clone RP23–451L8, coordinates 74787760 bp to 74991110 bp and clone RP23–118A6, coordinates 17908843 bp to 18113246 bp; BAC PAC Resource Center at the Children’s Hospital Oakland Research Institute, Oakland, CA), and unchanged regions (chromosome 10 clone CITB-CJTB-047K7 containing marker D10Mit T49 at coordinates 6066401 bp to 6066505 bp, and clone RP23–421E11, coordinates 81701304 bp to 81701622 bp; BAC PAC Resource Center at the Children’s Hospital Oakland Research Institute) as determined by array comparative genomic hybridization analyses were selected. All of the coordinates are based on the February 2003 freeze of the mouse genome assembly at http://genome.ucsc.edu. DNA templates for FISH probes (200 ng) were digested with DpnII (New England Biolabs, Beverly, MA), purified with QiQuick PCR purification columns (QiaGen, Valencia, CA), and random prime-labeled using the BioPrime DNA Labeling kit (Invitrogen) with either Cy3-dUTP (Amersham Biosciences, Piscataway, NJ) or Alexa 488-dUTP (Molecular Probes). The labeled samples were purified separately using G-50 mini-spin columns (Amersham), coprecipitated with 50 μg of mouse Cot-1 DNA (Invitrogen), and resuspended in 20 μl of hybridization buffer (50% formamide/2× SSC/10% dextran sulfate/2% SDS) before denaturation at 72°C for 15 min.

Analysis. Quantification was performed using a Zeiss Axioplan microscope (Oberkochen, Germany) at 1000× magnification under oil immersion. From the ventral ear leaflet of each animal, 50 labeled nuclei were counted from a minimum of four mice per time point. The data shown reflect the percentage of an average copy number ratio of chromosome 5 (Cy3 signals) to chromosome 10 (Alexa 488 signals) for each animal. To optimize the sensitivity for the low copy number changes in hyperplasias, scoring was limited to nuclei of basal keratinocytes that were within the first two cell layers adjacent to the basement membrane that demonstrated hybridization signals for both fluorochromes.

RESULTS

TIMP-1 mRNA Expression Increases during Neoplastic Progression in HPV16 Transgenic Mice. In studies of human cancer, many groups have documented increased expression of hTIMP-1 mRNA as compared with adjacent premalignant or distal normal control tissue (32, 43, 44). Using K14-HPV16 transgenic mice, we sought to examine the spatial and temporal expression patterns of TIMP family members during epithelial neoplastic progression and to determine the functional significance of TIMP-1 during that progression (25, 28). We used real-time PCR to quantify the amount of TIMP-1 mRNA in tissue samples representing distinct stages of neoplastic development (i.e., hyperplastic, dysplastic, and SCCs) as compared with normal skin (Fig. 1A). These data revealed an incremental increase in TIMP-1 mRNA at each neoplastic stage similar to reports for human carcinoma development (32, 43, 44).

To determine the spatial and temporal expression patterns of TIMP-1 mRNA expression in neoplastic skin, we used in situ hybridization analysis on neoplastically staged paraffin-embedded tissue sections (Fig. 1, B–G). Whereas TIMP-1 mRNA was not observed in non-neoplastic normal skin (Fig. 1B), it was detected diffusely within the epidermis and focally in discrete areas of the dermal stroma in hyperplasias and dysplasias (Fig. 1, C and D). In contrast to the diffuse expression in premalignant tissue, expression of TIMP-1 mRNA was increased focally in malignant keratinocytes at the invasive edges of Grade I and Grade II SCCs with persistent low-level expression in tumor-associated stromal cells (Fig. 1, E and F). TIMP-1 mRNA was not observed in lymph nodes with or without SCC metastases (Fig. 1G).

TIMP mRNAs Are Not Coordinately Regulated during Squamous Carcinogenesis. mRNA expression of TIMP family members is known to be regulated differentially during embryonic development (3) and in some pathologic disease states (45). To determine whether
the mRNAs for TIMP-2, -3, or -4 were expressed coordinately with TIMP-1 (spatially and/or temporally), mRNA expression of TIMP-2, -3, and -4 was examined on adjacent tissue sections by in situ hybridization analysis (data not shown), which demonstrated TIMP-2 and -3 mRNA expression in follicular epithelial and ear pericartilage cells in negative littermate skin, whereas in neoplastic skin, their expressions were increased incrementally in neoplastic keratinocytes throughout neoplastic progression and were most prominent in Grade 1 well-differentiated SCCs. Expression of TIMP-4 mRNA was not observed in either wild-type skin or any of the neoplastic stages from HPV16 mice. These data suggest that TIMP-2, -3, and -4 mRNAs are not expressed coordinately with TIMP-1 mRNA during squamous epithelial carcinogenesis.

**TIMP-1 Enhances Epithelial Carcinogenesis.** The progressive increase and distinctive spatial expression pattern of TIMP-1 mRNA observed during neoplastic progression in HPV16 mice suggested that TIMP-1 might contribute functionally to neoplastic development by mechanisms distinct from those regulated by TIMP-2 or -3. To test this hypothesis and to assess the functional significance of increased TIMP-1 mRNA expression during neoplastic progression, we took a genetic approach using TIMP-1 transgenic mice wherein a hTIMP-1 genetic approach using TIMP-1 transgenic mice wherein a hTIMP-1

**Histopathologic analysis of HPV16/βA-hT1− control mice revealed that their increased number was caused by increased incidence of SCCs (64.3% versus 55.4% in HPV16/βA-hT1− mice; P = 0.0048, log-rank analysis) and MACs (21.7% versus 10.8% in HPV16/βA-hT1− mice; P = 0.0131, log-rank analysis), whereas SCC grade (Fig. 2C) and frequency of lymphatic metastases were not significantly different between the two cohorts (Fig. 2B).

**Decreased MMP Activity and Increased Matrix Stability in HPV16/βA-hT1+ Mice.** The observed increase of SCCs and MACs in HPV16/βA-hT1− mice suggested that TIMP-1 potentiated the frequency of malignant conversion; however, the underlying biological mechanisms involved in this potentiation were not clear.

To determine how presence of kTIMP-1 protein correlated with altered neoplastic progression in HPV16/βA-hT1+ mice, we first used an ELISA to determine the amount of kTIMP-1 in (non-HPV16) βA-hT1+ versus βA-hT1− serum (Fig. 3A) and in neoplastically staged tissue lysates from HPV16/βA-hT1− mice and found that kTIMP-1 protein increased from ~0.5 ng/mg in hyperplastic skin to ~1.5 ng/mg in carcinomas (Fig. 3B). Because the most notable bioactivity (at high concentrations) of TIMP-1 is its ability to inhibit MP activity (1), we asked whether the increased levels of TIMP-1 in dysplasia and/or SCCs altered MP activity in those tissues. To test this, we used an in vitro gelatinase assay to determine total gelatinolytic activity in HPV16/βA-hT1+ and HPV16/βA-hT1− tissues derived from distinct stages of neoplastic progression (Fig. 3C). In early hyperplastic and dysplastic tissues, gelatinolytic activity was not significantly different between lysates derived from the two cohorts.
TIMP-1 ALTERS SUSCEPTIBILITY TO CARCINOGENESIS

(Fig. 3C). In contrast, carcinoma tissue lysates derived from HPV16/βA-hT1+ skin had an increase in total gelatinolytic activity compared with lysates from histopathologically similar HPV16/βA-hT1+ carcinomas (89.5 versus 51.1 relative fluorescence units/min/μg; P = 0.0392, Mann-Whitney two-tailed analysis; Fig. 3C) but did not demonstrate any changes in abundance of either pro or active species of MMP-2 and MMP-9 (Fig. 3D). In combination, these data suggested that increased hTIMP-1 levels in HPV16/βA-hT1+ carcinomas (~1.5 ng/mg) were sufficient to inhibit gelatinolytic activity present in SCCs by post-translational inhibition of gelatinolytic MMPs and/or other MP family members.

To assess functionally whether ECM architecture was altered in HPV16/βA-hT1+ dysplasias and/or carcinomas resulting from decreased gelatinolytic activity in vivo, we examined histologically the status of collagen fibrils in situ by picrosirius red staining (39, 40), an analysis that allows distinction between thinner reticular collagen versus thicker collagen fibrils based on colored birefringence differences (Fig. 4; Refs. 40 and 41). Qualitatively, polarization microscopic analysis of the picrosirius red staining in dysplasias and carcinomas from HPV16/βA-hT1+ mice suggested that stroma adjacent to dysplasias (Fig. 4A) and tumor nests (Fig. 4C) contained a combination of thick and thin collagen fibers that were predominately weakly birefringent. In contrast, in HPV16/βA-hT1+ mice, stroma adjacent to dysplastic epidermis (Fig. 4B) and within carcinomas (Fig. 4D) was almost devoid of thin weakly birefringent collagen fibers but was instead composed predominately of more intensely birefringent thicker fibers. Quantitative morphometric analysis of the picrosirius red staining between the two cohorts was different significantly at the dysplastic and carcinoma stages, with a more than twofold increase in the percentage of the intensely birefringent collagen fibers in the HPV16/βA-hT1+ carcinomas (6.5% versus 15.0%; P = 0.0317, Mann-Whitney two-tailed analysis) and an ~1.8-fold increase at the dysplastic stage (37.0% versus 69.1%; P = 0.0043, Mann-Whitney two-tailed analysis). Taken together, these data suggest that although elevated levels of TIMP-1 in dysplasias and carcinomas stabilize collagenous ECM in HPV16/βA-hT1+ mice, they do not impede conversion of premalignant dysplasias into carcinomas, invasion of carcinomas into ectopic stroma, or metastatic spread of primary carcinomas.

TIMP-1 Potentiates Keratinocyte Hyperproliferation. Acquisition of a hyperproliferative state is an intrinsic property of many neoplastic cell types (46). Accordingly, we have reported previously that keratinocyte hyperproliferation increases incrementally during neoplastic progression in HPV16 mice and, in part, characterizes progression between premalignant stages (25, 28). In addition, we have shown that keratinocyte hyperproliferation is attenuated by ablating MMP-9 activity in HPV16 mice and as a consequence decreases the incidence of SCCs (26). Because TIMP-1 regulates MMP-9 activity in vivo and in vitro (1, 4) and inhibits tissue gelatinase activity in vivo (Fig. 3C), while also demonstrating mitogenicity toward keratinocytes, albeit indirectly (7, 47), we sought to determine whether the increased tumor incidence in HPV16/βA-hT1+ mice was associated with an enhanced keratinocyte proliferation index or alternatively whether increased expression of TIMP-1 in HPV16 mice phenocopied our previous results with HPV16/MMP-9 homozygous null mice and attenuated keratinocyte proliferation (26). To test these hypotheses, we examined keratinocyte proliferative indices in hyperplastic, dysplastic, and SCCs and their lymphatic metastases in HPV16/βA-hT1+ and control mice (Fig. 5). Qualitatively, BrdU-immunoreactivity of tissue sections suggested that in hyperplastic and dysplastic tissues of HPV16/βA-hT1+ mice, a higher percentage of keratinocytes were proliferating as compared with histopathologically matched HPV16/βA-hT1− littermates at all of the neoplastic stages (data not shown). Quantification of BrdU-positive keratinocytes in situ supported this observation and revealed that HPV16/βA-hT1+ keratinocytes in early hyperplastic tissue (1 month of age) attained a hyperproliferative state (23.9% in HPV16/βA-hT1+ versus 16.3% in HPV16/βA-hT1−; P = 0.023, Mann-Whitney) more commonly associated with late dysplastic tissue characteristic of 6-month-old transgenic HPV16/βA-hT1+ animals (Fig. 5A). At the later time point in dysplastic HPV16/βA-hT1+ skin, hyperproliferation indices more resembled carcinomas than dysplastic epidermis (24.1% in HPV16/βA-hT1+ versus 18.5% in HPV16/βA-hT1−; P = 0.014, Mann-Whitney); however, after malignant conversion, differences between the two genotypes were indistinguishable (Fig. 5A).

To determine how transgenic expression of hTIMP-1 regulates the observed keratinocyte hyperproliferation in vivo in premalignant...
oxynucleotidyl transferase-mediated nick end labeling (TUNEL) reaction was performed. Apoptotic index was quantified as the percentage of TUNEL-positive keratinocytes at distinct stages of neoplastic development in the two cohorts of mice. Apoptotic index was quantified using the terminal deoxynucleotidyl transferase-mediated nick end labeling assay on staged neoplastic tissue sections adjacent to those used previously to assess proliferation and revealed that apoptotic indices were similar in HPV16/βA-hT1 + mice and their littermate controls in all of the stages of neoplastic development in histopathologically matched sections (Fig. 5B). Taken together, these data imply that the increased proliferation index observed during early neoplastic progression in HPV16/βA-hT1 + was the result of the mitogenic properties, direct or indirect, of TIMP-1 and independent of apoptotic cell death by TIMP-1 in this system.

Because TIMP-1 can regulate recruitment of inflammatory cells and activation of angiogenesis in some contexts (4, 32), and because we have previously reported inflammation and angiogenesis to be rate-limiting stage-specific characteristics of neoplastic progression in HPV16 transgenic mice (26, 27, 50), we also assessed the profile of inflammatory cells infiltrating neoplastic tissue (e.g., mast cells and neutrophils) and onset and organization of angiogenic vasculature during neoplastic progression. We found no quantifiable difference by any of the parameters tested at 1 month, 4 months, and 6 months and in carcinomas of HPV16/βA-hT1 + and HPV16/βA-hT1 − mice (data not shown). Our interpretation of these data is that increased tumorigenicity in HPV16/βA-hT1 + mice results from keratinocyte hyperproliferation caused by chronic expression of hTIMP-1 in (at-risk) early neoplastic keratinocytes.

Accelerated Onset of Genomic Instability in Hyperplastic HPV16/βA-hT1 + Mice. Recurrent genome copy number aberrations in proliferating neoplastic cells are a common feature of human and murine cancers and are believed to contribute to tumor evolution by copy number-induced alterations in gene expression (51–53). Using array-based comparative genomic hybridization analysis to examine the complexity of genomic copy number changes associated with epithelial carcinogenesis in HPV16 mice, we found recurrent copy number gains on chromosome 5 in 80% of SCCs, whereas copy...
number changes on chromosome 10 are rare and occur in fewer than 1% of carcinomas examined (n = 30). Because low-level expression of TIMP-1 in early premalignant tissue potentiates keratinocyte hyperproliferation, we determined whether it also might potentiate appearance of an aneuploid genotype and thereby enhance malignant risk. We used dual-color FISH analysis with markers for chromosome 5 and chromosome 10 on hyperplastic and dysplastic tissue sections from 1-month-old and 6-month-old HPV16/βA-hT1− and HPV16/βA-hT1+ mice (Fig. 6). Fifty FISH measurements were taken from each tissue; four to six tissues were examined for each histopathologic stage; and two independent loci were examined for each chromosome.

Chromosome 5 and 10 FISH analysis of nuclei in 1-month-old hyperplastic HPV16/βA-hT1− keratinocytes showed a negligible increase in chromosome 5 signals relative to chromosome 10 compared with nuclei in negative littermate diploid control tissue, whereas nuclei of 6-month-old dysplastic keratinocytes in HPV16/βA-hT1− tissue showed a significant relative increase in chromosome 5 signals (P = 0.0095, Mann-Whitney two-tailed) compared with the same

6 R. Diaz and L. M. Coussens, unpublished observations.

DISCUSSION

The present study reveals that TIMP-1 functionally contributes to epithelial cancer development in tumor-prone transgenic mice and is not regulated coordinately with other TIMP family members. We found that TIMP-1 enhanced keratinocyte hyperproliferation and accelerated appearance of genomic copy number abnormalities in early premalignant cells, thereby enhancing their susceptibility to undergo malignant conversion. In addition, in fully malignant tissue, TIMP-1 effectively inhibited (MMP) gelatinolytic activity and stabilized collagen matrices in vivo but did not inhibit invasion of malignant cells into ectopic tissue compartments or metastatic spread of primary carcinomas. The combined implications of these data are that TIMP-1 can enhance neoplastic risk while also stabilizing tumor stroma, and provide additional evidence that late-stage therapies mimicking TIMP-1 inhibition of MP activity will have limited clinical efficacy.

TIMP-1 and Inhibition of MP Activity. Enzymes that initiate remodeling of the ECM have long been viewed as essential for tumor development (54–56). Neoplastic cells were thought initially to produce these enzymes, thus permitting invasion into ectopic tissues, entry and exit from vasculature, and metastasis to distant organs. MMPs were prime candidates for these activities because MMP family members degrade collectively all of the structural components of the ECM (in vitro) and were found to have increased expression and activity in tissues undergoing various types of pathologic remodeling, including cancer (57). Additional evidence supporting the hypothesis that MMPs were critical regulators of invasion and metastasis came from studies of their natural tissue inhibitors, TIMPs. Several groups demonstrated that either overexpression or TIMPs or i.p. injection of recombinant TIMP-1 reduced experimental metastasis formation (58–63), whereas functional studies exploiting transgenic technology additionally revealed TIMP/MMP significance during carcinogenesis (e.g., TIMP-1 overproduction slowed chemical carcinogenesis in skin; Ref. 64) and inhibited SV40 large T antigen-induced liver (65) and MMP-3/stromelysin-induced mammary carcinogenesis (20, 66). However, paradoxically elevated TIMP-1 mRNA expression also was reported to correlate with malignant progression and poor clinical prognosis of several human cancers (12, 67, 68).

To determine whether increased TIMP-1 expression would slow de novo carcinogenesis as hypothesized initially or alternatively potentiate carcinogenesis as suggested by observations associating TIMP-1 with poor clinical outcome, we took a genetic approach using a mouse model of epithelial carcinogenesis harboring a TIMP-1 transgene. Results from the current study provide insight into the duality of TIMP-1 as a modifier of neoplastic progression and highlight the irrelevance of inhibiting MMP activity once tumors have already formed. Expression of TIMP-1 in malignant lesions of HPV16 mice is an efficacious inhibitor of gelatinase activity (Fig. 3) and effectively stabilizes collagen matrices in neoplastic tissue—effects that are consistent with TIMP-1 acting as an MP inhibitor. However, the net
effect of these bioactivities is without consequence in limiting malignant conversion, malignant growth, or metastatic spread of carcinomas—results that are remarkably similar to those reported for human clinical trials testing the efficacy of MP inhibitors in patients with late-stage neoplastic disease (69, 70), for whom treatment with synthetic MP inhibitors generally failed to show any benefit compared with placebo in terms of overall survival or time to progression (71, 72).

Heppner-Goss et al. (24) compared the effects of transgenic TIMP-1 expression in a mouse model of intestinal neoplasia and found that TIMP-1 enhanced tumor multiplicity; however, when those same mice were treated throughout neoplastic progression with batimastat, a broad spectrum MP inhibitor (73), there was a reduction in tumorigenicity (24). This seeming paradox can be explained because TIMP-1 is a multifunctional protein whose activities include inhibition of MP activity at high concentration as opposed to mitogenic activities at lower concentrations (2, 74), in contrast to batimastat, which functions primarily as an MP inhibitor. One interpretation of these data is that inhibiting MP activity may be more efficacious if performed before the emergence of malignant disease. This hypothesis has been borne out by Bergers et al. (75), who reported that treatment of pancreatic islet carcinomas with batimastat was without effect on the persistence or continued growth of malignant tumors, whereas treatment of precursor hyperplastic lesions reduced their progression into more advanced angiogenic dysplasias, suggesting that the effective window for targeting MP activity as an anticancer strategy is early in the neoplastic cascade. When combined with functional studies examining transgenic mouse models of de novo carcinogenesis harboring homozygous null mutations in individual MMP genes (26, 76, 77), the implication is that targeting MPs with synthetic inhibitors devoid of mitogenic bioactivity would yield more desirable outcomes if performed before overt tumor formation.

**Procarcinogenic Activities of TIMP-1:**

If TIMP-1 effectively inhibits MP activity in vivo, why then is enhanced expression of hTIMP-1 protumorigenic? Our findings suggest that induction of hyperproliferation versus regulation of ECM remodeling are stage- and concentration-dependent responses to TIMP-1 in HPV16 transgenic mice and represent in vivo evidence supporting procarcinogenic roles for TIMP-1 during carcinogenesis.

Previous reports using in vitro cell-based assays have demonstrated (indirect) mitogenic properties of TIMP-1 in a wide range of cell types (6, 8), including keratinocytes (7, 47), and using altered non-MMP inhibitory versions of TIMP-1, others have shown that TIMP-1’s mitogenic properties are separate and distinct from its MMP inhibitory capabilities (9, 12). Moreover, in addition to interacting with MPs, TIMP-1 binds to a non-MP cell surface protein with high affinity ($K_d = 100$ pm; Ref. 8). Diverse mechanisms have been suggested for how TIMP-1 may induce proliferation in vivo in addition to its indirect mitogenic properties (7, 8, 12, 47, 78). In a mammary carcinoma transplantation model, TIMP-1 expression correlated with enhanced epithelial proliferation largely because of increased expression of VEGF-A mRNA and subsequent enhanced angiogenesis (79). In contrast, using lymphoma cells, TIMP-1 was found to stimulate tumor growth by reciprocally decreasing apoptotic indices (80). Paradoxically, in a mouse model of intestinal neoplasia (e.g., min mice), enhanced TIMP-1 expression resulted in increased tumor multiplicity; however, changes in the proliferative status of neoplastic cells and angiogenesis were not examined (24).

Proteolytic activity of MMPs and other MP families (e.g., ADAMs and/or ADAM-TS members) has been linked to regulation of proliferation via proteolytic activation of growth inhibitory molecules, such as transforming growth factor-β, and activation of growth-promoting factors (e.g., insulin-like growth factor ligands and members of the epidermal growth factor family; Refs. 4 and 57). As such, it is reasonable to conclude that in addition to TIMP-1 exerting indirect mitogenic activity in vivo and in cell-based assays in vitro, the possibility cannot be ruled out that at low concentrations (e.g., during early neoplastic progression), TIMP-1 regulates the bioactivity of a growth-restricting factor whose inhibition releases keratinocyte proliferative potential.

Regardless of the mechanism, how does increased hyperproliferative activity caused by TIMP-1 translate into increased tumorigenicity in HPV16 mice or in mice predisposed to intestinal neoplasia? Mechanisms linking cell division and aneuploidy have been well characterized (81, 82) and include, for example, errors in chromosome segregation during mitosis caused by aberrant centrosome duplication (83, 84). Regarding mechanisms of carcinogenesis resulting from HPV-induced tumorigenicity, it has been reported that the HPV oncoprotein E7 induces cell division-associated aneuploidy by enhancing the activity of cdk2/cyclin E and cdk2/cyclin A complexes, both of which are involved in regulating centrosome duplication in vivo (85). Thus, when the potential for chromosomal instability has been primed (by E7-induced centrosome errors), our data support a model in which low-level expression of TIMP-1 enhances keratinocyte hyperproliferation and results in a higher fraction of aneuploid cells at risk to undergo malignant conversion caused by earlier accumulation of E7-induced chromosomal aberrations. Perhaps in human cancers, as in the HPV16 and min mouse models, late-stage MP inhibition and ECM stabilization are not sufficient to block neoplastic cells that already have been programmed genomically, resulting in loss of cell cycle checkpoint control, hyperproliferation, and other events involved in malignant conversion. Premalignant chromosomal aberrations have been detected in several human malignancies (86–88), and notably early head and neck SCCs provide a predictive value for malignant conversion (89, 90). Taken together and in conjunction with results from the present study, we suggest that of the many events that must take place to produce a bone fide tumor, intrinsic genomic changes involved in manifesting cancer likely occur at an early stage in the evolutionary process and, in part, set the stage for additional deregulation of cell intrinsic events involved in carcinogenesis. In HPV16 mice at least, genomic aberrations could represent one of these intrinsic neoplastic events subject to regulation by TIMP-1-induced hyperproliferation. Given the observation that TIMP-1 assumes a nuclear localization after plasma membrane binding in some cell types (91, 92), we cannot rule out the possibility that TIMP-1 also may affect directly (or indirectly) chromosome integrity in E6/E7-positive keratinocytes in HPV16 mice; however, examining this possibility awaits generation of reagents capable of detecting TIMP-1 protein localization in situ.

**Multiplicity of Pathways in HPV16 Mice.**

If increased TIMP-1 potentiates neoplastic risk, does homozygous loss of TIMP-1 attenuate that same risk? We addressed this question by intercrossing HPV16 mice into a TIMP-1 homozygous null background (93) and found no discernible difference between HPV16/T1$^{+/−}$ (n = 109) and HPV16/T1$^{−/−}$ (n = 51) cohorts. Our interpretation of this seeming disparity illuminates the functional contribution of TIMP-1 as a modifier of carcinogenesis that is sufficient but is not necessary for promoting the multiplicity of changes occurring during tumor development. We hypothesize that these data support a model reflecting the fact that multiple discrete pathways must be altered and/or activated for full progression to the tumor state and, furthermore, that a minimal number or combination of these pathways must be compromised to exert a detectable attenuation in tumorigenesis. Hence, one implication of this is that factors such as MMP-9 would participate in multiple pathways, whereas conversely TIMP-1 exerts regulatory pressure on fewer pathways necessary for manifesting a tumor. In
TIMP-1 ALTERS SUSCEPTIBILITY TO CARCINOGENESIS


ACKNOWLEDGMENTS

We thank Zena Werb for providing β1A1T1 transgenic mice; Jake Lee and Andre Whittkin for technical assistance; and Joe Gray, Zena Werb, Koei Chin, and members of the Coussens laboratory for fruitful discussion and critical comments.

REFERENCES


70. Hidalgo, M., and Eckhardt, S. G. Development of matrix metalloproteinase inhibitors

68. Schrohl, A. S., Christensen, I. J., Pedersen, A. N., Jensen, V., Mouridsen, H., Murphy, G., Foekens, J. A., Brunner, N., and Holten-Andersen, M. N. Tumor tissue concen-

66. Sternlicht, M. D., Bissell, M. J., and Werb, Z. The matrix metalloproteinase strome-

67. Murashige, M., Miyahara, M., Shiraishi, N., Saito, T., Kohno, K., and Kobayashi, M.

65. Martin, D. C., Rourke, U., Sanchez-Sweatman, O. H., Orr, F. W., and Khokha, R. Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic

64. Buck, T. B., Yoshiji, H., Harris, S. R., Bunce, O. R., and Thorgeirsson, U. P. The


64. Buck, T. B., Yoshiji, H., Harris, S. R., Bunce, O. R., and Thorgeirsson, U. P. The

65. Martin, D. C., Ru

66. Sternlicht, M. D., Bissell, M. J., and Werb, Z. The matrix metalloproteinase stroma-

67. Murashige, M., Miyahara, M., Shiraishi, N., Saito, T., Kohno, K., and Kobayashi, M.

68. Schrohl, A. S., Christensen, I. J., Pedersen, A. N., Jensen, V., Mouridsen, H., Murphy, G., Foekens, J. A., Brunner, N., and Holten-Andersen, M. N. Tumor tissue concen-

69. Zucker, S., Cao, J., and Chen, W. T. Critical appraisal of the use of matrix metallo-


71. Coussens, L. M., B. Fingleton, and, and Matrisian, L. M. Matrix metalloproteinase


73. Khokha, R. Suppression of the tumorigenic and metastatic abilities of murine B16–

74. Brinckerhoff, C. E., and Matrisian, L. Matrix metalloproteinases: a tail of a frog that

75. Pinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo,

76. Pinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo,

77. Zucker, S., Cao, J., and Chen, W. T. Critical appraisal of the use of matrix metallo-

78. Zucker, S., Cao, J., and Chen, W. T. Critical appraisal of the use of matrix metallo-


80. Guedez, L., McMarlin, A. J., Kingma, D. W., Bennett, T. A., Stepler-Stevenson, M., and Stepler-Stevenson, W. G. Tissue inhibitor of metalloproteinase-1 alters the tu-

81. Pinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo,

82. Buck, T. B., Yoshiji, H., Harris, S. R., Bunce, O. R., and Thorgeirsson, U. P. The

83. D Assoro, A. B., Lingle, W. L., and Salisbury, J. L. Centrosome amplification and the


86. D Assoro, A. B., Lingle, W. L., and Salisbury, J. L. Centrosome amplification and the


88. Sugai, T., Jenkins, G. J., Parry, E. M., D’Souza, F. R., Griffiths, A. P., Toffazzal,

89. Pinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo,

90. Pinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo,

91. Zhao, W. Q., Li, H., Yamashita, K., Guo, X. K., Hoshino, T., Yoshida, S., Shinya, T.,

92. Pinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo,


94. Pinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo,

95. Pinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo,

96. Pinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo,

97. Pinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo,

98. Pinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo,

99. Pinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo,
TIMP-1 Alters Susceptibility to Carcinogenesis

Jin-Sae Rhee, Robert Diaz, Lidiya Korets, et al.

*Cancer Res* 2004;64:952-961.

Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/64/3/952

Cited articles
This article cites 91 articles, 21 of which you can access for free at:
http://cancerres.aacrjournals.org/content/64/3/952.full#ref-list-1

Citing articles
This article has been cited by 8 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/64/3/952.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/64/3/952.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.